// App-Quantinova.ai

: Targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2 crossover patient outcomes

Researchers

Presenter

  • Pallav L. Shah

Principal Investigators

  • Arschang Valipour

  • Christophe Pison

  • Christian Schumann

  • Peter Bonta

  • Romain Kessler

  • Wolfgang Gesierich

  • Kaid Darwiche

  • Bernd Lamprecht

  • Dirk Skowasch

  • Dirk-Jan Slebos

Medical Centers

  • Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

  • Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Vienna, Austria

  • CHU de Grenoble – Hopital Michallonandsteiner-Institute for Lung Research and Pulmonary Oncology, Grenoble, France

  • Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin, Kempten, Germany

  • UMC Amsterdam Meibergdreef , Amsterdam, Netherlands

  • CHRU de Strasbourg-Nouvel Hopital Civil , Strasborg, France

  • Helios Klinikum München West, München, Germany

  • Universitätsmedizin Essen - Ruhrlandklinik, Essen, Germany,

  • Johannes Kepler University Linz, Linz, Austria

  • Universitatsklinikum Bonn, Bonn, Germany

  • University of Groningen, Groningen, Netherlands

Locations

  • United Kingdom

  • Austria

  • France

  • Germany

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Catalase

  • Bone Morphogenetic Protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • NA

Study Id's

  • NCT02058459

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved